- Home
- RBOT vs VIGL Comparison
RBOT vs VIGL Comparison
Compare RBOT & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- VIGL
- Stock Information
- Founded
- RBOT 2014
- VIGL 2020
- Country
- RBOT United States
- VIGL United States
- Employees
- RBOT N/A
- VIGL N/A
- Industry
- RBOT Medical Specialities
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- VIGL Health Care
- Exchange
- RBOT Nasdaq
- VIGL Nasdaq
- Market Cap
- RBOT 88.6M
- VIGL 89.3M
- IPO Year
- RBOT N/A
- VIGL 2022
- Fundamental
- Price
- RBOT $15.00
- VIGL $2.76
- Analyst Decision
- RBOT Hold
- VIGL Strong Buy
- Analyst Count
- RBOT 2
- VIGL 5
- Target Price
- RBOT $10.25
- VIGL $21.00
- AVG Volume (30 Days)
- RBOT 39.9K
- VIGL 2.7M
- Earning Date
- RBOT 03-03-2025
- VIGL 03-25-2025
- Dividend Yield
- RBOT N/A
- VIGL N/A
- EPS Growth
- RBOT N/A
- VIGL N/A
- EPS
- RBOT N/A
- VIGL N/A
- Revenue
- RBOT N/A
- VIGL N/A
- Revenue This Year
- RBOT N/A
- VIGL N/A
- Revenue Next Year
- RBOT N/A
- VIGL N/A
- P/E Ratio
- RBOT N/A
- VIGL N/A
- Revenue Growth
- RBOT N/A
- VIGL N/A
- 52 Week Low
- RBOT $4.27
- VIGL $1.49
- 52 Week High
- RBOT $19.00
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- RBOT 58.49
- VIGL 70.15
- Support Level
- RBOT $11.73
- VIGL $2.54
- Resistance Level
- RBOT $13.92
- VIGL $2.88
- Average True Range (ATR)
- RBOT 1.06
- VIGL 0.22
- MACD
- RBOT 0.10
- VIGL 0.03
- Stochastic Oscillator
- RBOT 93.70
- VIGL 85.19
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.